StreetInsider.com News Articles

Form SCHEDULE 13G Imunon, Inc. Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:50:00 -0500

si-local-file:///var/storage/secattach/20260217/26016333.html

Form SCHEDULE 13G Imunon, Inc. Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:50:00 -0500

si-local-file:///var/storage/secattach/20260217/26016333.html

Imunon (IMNN) PT Raised to $25 at H.C. Wainwright

Fri, 06 Feb 2026 06:44:51 -0500

(Updated - February 6, 2026 6:44 AM EST)

H.C. Wainwright analyst Emily Bodnar raised the price target on Imunon (NASDAQ: IMNN) to $25.00 (from $14.00) while maintaining a Buy rating.

The analyst commented: "This morning, Imunon announced a strategic restructuring which will eliminate headcount not essential to the ongoing Phase 3 OVATION 3 trial in newly diagnosed advanced ovarian cancer patients, and to refine job descriptions for employees in order to reduce operating expenses while focusing resources on advancing the pivotal trial. As part of the restructuring, the company's Chief Science Officer, Khursheed Anwer, will be retiring after 12 years with the

Imunon (IMNN) PT Raised to $25 at H.C. Wainwright

Fri, 06 Feb 2026 06:44:51 -0500

(Updated - February 6, 2026 6:44 AM EST)

H.C. Wainwright analyst Emily Bodnar raised the price target on Imunon (NASDAQ: IMNN) to $25.00 (from $14.00) while maintaining a Buy rating.

Imunon CSO Khursheed Anwer to retire February 20

Thu, 05 Feb 2026 08:11:26 -0500

Imunon Inc. (NASDAQ: IMNN) announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire from the company effective February 20, 2026.

Anwer informed the company of his retirement intent on February 2, 2026. The company stated his departure involves no disagreements with management.

Under a retirement and consulting agreement executed February 4, 2026, Anwer will provide consulting services to Imunon through December 31, 2026. The company will pay him a monthly retainer of $10,000 during this consulting period.

The agreement includes additional compensation for Anwer consisting of continued base salary payments for 12 months following his retirement date and company-paid

Imunon CSO Khursheed Anwer to retire February 20

Thu, 05 Feb 2026 08:11:26 -0500

Imunon Inc. (NASDAQ: IMNN) announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire from the company effective February 20, 2026.

Anwer informed the company of his retirement intent on February 2, 2026. The company stated his departure involves no disagreements with management.

The agreement includes additional compensation for Anwer consisting of continued base salary payments for 12 months following his retirement date and company-paid

Form 8-K Imunon, Inc. For: Feb 02

Thu, 05 Feb 2026 08:06:00 -0500

si-local-file:///var/storage/secattach/20260205/25951121.html

Form 8-K Imunon, Inc. For: Feb 02

Thu, 05 Feb 2026 08:06:00 -0500

si-local-file:///var/storage/secattach/20260205/25951121.html

IMUNON restructures operations to focus on phase 3 ovarian cancer trial

Thu, 05 Feb 2026 08:05:10 -0500

IMUNON Inc. (NASDAQ: IMNN) announced a strategic reorganization that will reduce headcount and operating expenses to focus resources on its phase 3 ovarian cancer clinical trial. The company also said Khursheed Anwer, executive vice president and chief scientific officer, will retire effective February 20, 2026, after nearly 12 years with the company.

The restructuring eliminates positions not essential to the OVATION 3 phase 3 trial and redefines job descriptions for remaining employees. According to the company, phase 3 study enrollment continues ahead of schedule.

Anwer led the initial development of IMUNON's TheraPlas platform technology during his tenure. "Dr. Khursheed Anwer's decision to

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

Thu, 05 Feb 2026 08:05:00 -0500

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study

Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company

Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing

LAWRENCEVILLE, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced a strategic reorganization that will eliminate headcount not essential to the Phase 3 trial and redefine the

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

Thu, 05 Feb 2026 08:05:00 -0500

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study

Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company

Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing

Form 3 Imunon, Inc. For: Jan 15 Filed by: CHURCH JEFFREY WAYNE

Tue, 20 Jan 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260120/25868210.html

Form 3 Imunon, Inc. For: Jan 15 Filed by: CHURCH JEFFREY WAYNE

Tue, 20 Jan 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260120/25868210.html

Form 8-K Imunon, Inc. For: Jan 07

Wed, 07 Jan 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260107/25821174.html

Form 8-K Imunon, Inc. For: Jan 07

Wed, 07 Jan 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260107/25821174.html

Imunon (IMNN) PT Lowered to $16 at Brookline Capital Markets

Wed, 07 Jan 2026 14:42:10 -0500

Brookline Capital Markets analyst Kemp Doliver lowered the price target on Imunon (NASDAQ: IMNN) to $16.00 (from $21.00) while maintaining a Buy rating.

The analyst comments "The recent registered direct offering raised $7MM in gross proceeds, extending the runway to Q3:2026 from Q1:2026 (prior to warrant exercises). Enrollment in the Phase 3 OVATION-3 trial continues, with site activation expected to accelerate through 2026. In parallel with clinical execution, the company is progressing CMC and manufacturing scale-up activities to support commercialization. Highlights from the company’s R&D Day are

Imunon (IMNN) PT Lowered to $16 at Brookline Capital Markets

Wed, 07 Jan 2026 14:42:10 -0500

Brookline Capital Markets analyst Kemp Doliver lowered the price target on Imunon (NASDAQ: IMNN) to $16.00 (from $21.00) while maintaining a Buy rating.

Form 4 Imunon, Inc. For: Jan 02 Filed by: Bragg Kimberly

Tue, 06 Jan 2026 16:12:00 -0500

si-local-file:///var/storage/secattach/20260106/25813392.html

Form 4 Imunon, Inc. For: Jan 02 Filed by: Bragg Kimberly

Tue, 06 Jan 2026 16:12:00 -0500

si-local-file:///var/storage/secattach/20260106/25813392.html

Form 4 Imunon, Inc. For: Jan 02 Filed by: Fritz Frederick J.

Tue, 06 Jan 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260106/25813312.html

Form 4 Imunon, Inc. For: Jan 02 Filed by: Fritz Frederick J.

Tue, 06 Jan 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260106/25813312.html

Form 4 Imunon, Inc. For: Jan 02 Filed by: Anwer Khursheed

Tue, 06 Jan 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260106/25813326.html

Form 4 Imunon, Inc. For: Jan 02 Filed by: Anwer Khursheed

Tue, 06 Jan 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260106/25813326.html

Form 4 Imunon, Inc. For: Jan 02 Filed by: Eylward Susan

Tue, 06 Jan 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260106/25813283.html

Form 4 Imunon, Inc. For: Jan 02 Filed by: Eylward Susan

Tue, 06 Jan 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260106/25813283.html